Douglas Lankler - Pfizer Executive Vice President General Counsel

PFIZ34
  

BRL 64.61  1.45  2.19%   

  President
Mr. Douglas M. Lankler is the Executive Vice President, General Counsel of Pfizer Inc. Mr. Lankler was corporate Secretary from January 2014 until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013. Executive Vice President, Chief Compliance Officer from December 2010 until February 2011. Senior Vice President and Chief Compliance Officer from January 2010 until December 2010. Senior Vice President, Deputy General Counsel and Chief Compliance Officer from August 2009 until January 2010. Senior Vice President, Associate General Counsel and Chief Compliance Officer from October 2006 until August 2009.
Age: 56  President Since 2014      
212 733 2323  https://www.pfizer.com

Douglas Lankler Latest Insider Activity

Tracking and analyzing the buying and selling activities of Douglas Lankler against Pfizer stock is an integral part of due diligence when investing in Pfizer. Douglas Lankler insider activity provides valuable insight into whether Pfizer is net buyers or sellers over its current business cycle. Note, Pfizer insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pfizer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Douglas Lankler over six months ago via Macroaxis 
Pfizer exotic insider transaction detected

Pfizer Management Efficiency

Pfizer Inc has return on total asset (ROA) of 0.1332 % which means that it generated profit of $0.1332 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 0.3551 %, meaning that it generated $0.3551 on every $100 dollars invested by stockholders. Pfizer management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 36.2 B in total debt with debt to equity ratio (D/E) of 0.44, which is about average as compared to similar companies. Pfizer Inc has a current ratio of 1.37, which is within standard range for the sector. Debt can assist Pfizer until it has trouble settling it off, either with new capital or with free cash flow. So, Pfizer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pfizer Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pfizer to invest in growth at high rates of return. When we think about Pfizer's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records

PRESIDENT Since

David PiacquadAmgen Inc
2014
David ReeseAmgen Inc
2018
Sean HarperAmgen Inc
2012
Murdo GordonAmgen Inc
2018
Jonathan GrahamAmgen Inc
2015
Esteban SantosAmgen Inc
2016
David MelineAmgen Inc
2014
Brian McNameeAmgen Inc
2013
Peter GriffithAmgen Inc
2020
Lori JohnstonAmgen Inc
2016
Stuart TrossAmgen Inc
2013
Cynthia PattonAmgen Inc
2012
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. PFIZER DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 79000 people. Pfizer Inc (PFIZ34) is traded on Sao Paolo Exchange in Brazil and employs 79,000 people.

Pfizer Inc Leadership Team

Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President of Global Established Pharma Bus.
Jennifer Damico, Controller VP
Frank DAmelio, CFO and Executive VP of Bus. Operations
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Director
James Smith, Director
Christopher CFA, VP Officer
Dennis Ausiello, Independent Director
Mikael Dolsten, President - Worldwide Research and Development
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President CTO and Digital Officer
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
David Denton, Chief VP
Alexander Mackenzie, Executive Vice President Chief Development Officer
DVM DVM, Chairman CEO
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Executive Vice President - Corporate Affairs
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Executive Vice President Chief Compliance and Risk Officer
Mikael MD, Dev Research
Dan Littman, Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President - Pfizer Essential Health
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Pfizer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Pfizer without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Focused Opportunities Now

   

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.